Results 241 to 250 of about 24,552 (280)
Some of the next articles are maybe not open access.
Breaking the BTK Killer's Cipher
Cryptologia, 2013For over 30 years, a serial killer terrorized Kansas and the surrounding areas, his modus operandi: Bind, Torture, Kill. While many are exceedingly familiar with the notorious BTK murders, few are aware of the existence of a cipher written by the BTK killer. This article introduces the BTK killer, the cipher system he employed, and the cryptanalysis of
openaire +1 more source
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
Archives of Pharmacal ResearchBruton's tyrosine kinase (BTK) is a therapeutically validated drug target. Small-molecule inhibitors of BTK have changed the treatment paradigms of multiple B-cell malignancies and evolved over three generations to overcome clinical challenges. Four drugs are now approved by the FDA, including the first-in-class drug ibrutinib and successively approved
openaire +2 more sources
Btk and BLNK in B cell development
2001Publisher Summary This chapter discusses the major advances in the study of Bruton's tyrosine kinase (Btk), especially the identification of the link between Btk and BLNK in the context of B cell development, with an attempt to incorporate these studies into a complete picture of the molecular framework of the Btk signaling pathway.
S, Tsukada, Y, Baba, D, Watanabe
openaire +2 more sources
The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors.
Clinical advances in hematology & oncology : H&ODespite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some toxicities can be life-threatening, such as cardiotoxicity.
Fateeha, Furqan, Nirav N, Shah
openaire +1 more source
Optimizing BTK Inhibition in Waldenström Macroglobulinemia
Journal of the National Comprehensive Cancer NetworkBruton tyrosine kinase (BTK) inhibitors have become a standard of care in the treatment of patients with Waldenström macroglobulinemia (WM) and are the only medications approved by the FDA to treat these patients. As more patients with WM are treated with BTK inhibitors in the United States and worldwide, it is essential to optimize this therapy by ...
Shayna, Sarosiek, Jorge J, Castillo
openaire +2 more sources
Discovery of novel BTK PROTACs for B-Cell lymphomas
European Journal of Medicinal Chemistry, 2021Qiong Xie, Yonghui Wang
exaly
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
International Journal of Molecular Sciences, 2021Chiara Brullo +2 more
exaly